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135cc (range, 228-630) respectively. The treatment plan was designed 
to deliver a dose of 50.0 Gy to the planning target volume at 2 Gy-
daily fractions, 5 days a week. The objective for the plans was the 
coverage of 95% of the PTV with the prescribed dose. Planning 
Objectives were placed to ensure that no more than 1% of the PTV 
will receive more than 107%.Planning objectives were also placed for 
normal structures as per the hospital protocol. Dose-volume 
histograms (DVH) for the target volume and the organs at risk (Small 
bowel,bladder, femoral heads, Rectum and healthy tissue) were 
compared for the 2 different techniques. Monitor units (MU) and 
delivery treatment time are also reported. 
Results: All plans achieved fulfilled objectives. Both IMRT and VMAT 
resulted in similar coverage of PTV. The difference between the doses 
to the normal structures for the two techniques was not significant. 
Conformity Factor (CF95%)for the PTV was 0.9778 ± 0.01 (VMAT), and 
0.9805 ± 0.013 (IMRT).Homogeneity Index (D5% - D95%/ D Pres) for PTV 
was 0.068 ± 0.01 for VMAT and 0.0596 ± 0.01 IMRT. 
Conclusions: For patients suffering from Carcinoma of Cervix, VMAT 
with 2 arcs was able to deliver equivalent treatment plan to IMRT in 
terms of PTV coverage with marginally inferior homogeneity Index. It 
provided a similar organ at risk sparing, reduced healthy tissue sparing 
(V5 and V10) and significant reductions of MU and treatment time per 
fraction with respect to IMRT. Factors like gamma index, reduction in 
delivery time and treatment monitor units are also discussed and 
reported. 
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Purpose/Objective: The purpose of this paper is to assess the 
importance of the variations in daily positioning in treatments of IMRT 
in head and neck cancer patients, in order to check whether PTVs 
margins are adequate. 
Materials and Methods: Ten consecutive head and neck patients with 
bilateral lymph nodes, previously treated with the integrated boost 
technique in 30 fractions (30 x 1.8 Gy to PTV1 and 30 x 2.25 Gy to 
PTV2), were recalculated using the same IMRT plan with a 5 mm 
displacement in all directions (longitudinal, lateral and vertical, 
positive and negative), which gives us a total of 60 cases. Variations in 
doses to both treatment volumes and organs at risk were evaluated, 
and for cases exceeding significative values, the same procedure was 
repeated with 3 mm displacements. 
Results: To assess the goodness of the results two parameters were 
used: the dose to the CTV2, considering invalid cases where the 
decrease in CTV2 volume coverage was greater than 1%, and the dose 
in the spinal cord, considering invalid those cases in which the volume 
receiving 50Gy exceeded 2cc. Thirteen of the sixty cases showed 
deviations greater than these values. In these cases the same 
procedure was repeated, now with deviations of 3 mm, and there 
were still two cases out of range. These two cases (patients 5 and 9) 
were recalculated with displacements of 2 mm in all directions, and 
there were no values out of range. 
  
Conclusions: We can conclude that with less or equal 2 mm 
displacement in any direction, IMRT treatments in patients with head 
and neck tumors are properly administered, and it is not necessary to 
correct the deviations up to 2 mm that can be observed in daily 
checks with the portal images. 
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Purpose/Objective: To investigate the feasibility of volumetric 
modulated arc therapy with SmartArc (VMAT-S) for endometrial 
cancer to achieve equivalent plan quality with higher delivery 
efficiency, against with intensity-modulated radiotherapy (IMRT) and 
helical tomotherapy (HT).  
Materials and Methods: Nine patients with endometrial cancer were 
retrospectively studied. Three plans were generated with VMAT-S, 
IMRT and HT for each patient. The dose distribution of planning target 
volume (PTV), organs at risk (OARs) and normal tissue were compared. 
The monitor units (MUs) and treatment delivery time were also 
evaluated. 
Results: The average homogeneity index was 1.06, 1.10 and 1.07 for 
VMAT-S, IMRT and HT plans. The V40 of rectum, bladder and pelvis 
bone decreased 9.0%, 3.0%, and 3.0% in VMAT-S compared with IMRT, 
respectively. The target coverage and OARs sparing were comparable 
between VMAT-S and HT. The average MU was 823, 1105 and 8403 for 
VMAT-S, IMRT and HT. The average delivery time was 2.6 minutes, 8.6 
minutes, and 9.5 minutes.  
Conclusions: VMAT-S provided comparable plan quality with 
significant shorter delivery time and less MUs compared with IMRT and 
HT for endometrial cancer. In addition, more homogeneous PTV 
coverage and superior OARs sparing in the medium to high dose region 
were observed in VMAT-S over IMRT.  
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Purpose/Objective: RT treatment-planning techniques may result in a 
uniform dose delivery to the PTV in prostate plans well within the 
homogeneity criteria as specified by the ICRU 83 (D98%> 95% and D2% < 
107%). However, increasing the inhomogeneity of the target dose to 
the PTV allows for a steeper dose gradient and subsequently reducing 
the dose delivery to the adjacent rectal wall and anal sphincter, and 
potentially reducing toxicity. 
Materials and Methods: A selection of 9 clinical prostate RT plans 
with substantial homogeneous target coverage was re-planned. For 
the new plans, conformity and OARs sparing were improved, at the 
cost of homogeneous target coverage. The inhomogeneity was kept 
within the ICRU 83 criteria. The target dose homogeneity in the PTV: 
HI=(D2%-D98%)/D50%, the parameter V64Gy for the rectal wall and the Dmean 
in the anal sphincter were determined. A comparison of these 
parameters is made between the original and the inhomogeneous 
plan. Additionally, the change in the underlying DVH-curves was 
monitored. 
Results: The homogeneity index in the PTV dose distribution HIPTV 
increased in all re-planned RT plans ranging from 51% to 105% 
compared to the original plan (HIorig avg=0.056, σ=0.006). The values of 
the parameters V64Gy for the rectal wall and Dmean for the anal 
sphincter decreased in all inhomogeneous plans. For the rectal wall 
the V64Gy parameter decreased down to -16%, and for the anal 
sphincter the Dmean decreased down to -7.6Gy, see figure. Out of the 9 
plans, 4 showed an overall drop of the DVH curve for the rectal wall, 
while the others showed some increase in the high dose regime. An 
increase in the inhomogeneity of the dose delivery to the PTV creates 
local hotspots, which is reason for concern when considering target 
position inaccuracy during treatment. 
 
 
